Dr. Sameem M. Abedin, MD
Hematology & Oncology (Hematology & Oncology Physician)
9200 W Wisconsin Ave
Milwaukee, WI 53226
Who else practices at this address →
Milwaukee County includes primary care (32% of residents) and mental health (34% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 123
Licensed in Illinois since 2014, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: Jefferson Medical College of Thomas Jefferson University
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
WI license 67714 -
Internal Medicine Physician
IL license 036135124 (first issued 2014; not renewed) · MI license 4301100128 · PA license MT195216
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Froedtert Memorial Lutheran Hospital Milwaukee, WI
- Thedacare Regional Medical Center - Appleton Inc Appleton, WI
- Froedtert South Inc. Kenosha, WI
Medical groups
- The Medical College of Wisconsin Inc (2,115 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 123
- Services billed
- 681
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 124 | 41 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 96 | 29 |
| Established patient office or other outpatient visit, 20-29 minutes | 90 | 38 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 76 | 28 |
| Established patient office or other outpatient visit, 40-54 minutes | 68 | 25 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Milwaukee, WI | 68 |
| Jakafi (ruxolitinib phosphate) | 56 |
| Prednisone Other prescribers in Milwaukee, WI | 46 |
| Fluconazole Other prescribers in Milwaukee, WI | 26 |
| Venclexta (venetoclax) | 23 |
| Ursodiol Other prescribers in Milwaukee, WI | 18 |
| Dexamethasone Other prescribers in Milwaukee, WI | 17 |
| Calquence (acalabrutinib maleate) | 17 |
| Allopurinol Other prescribers in Milwaukee, WI | 14 |
| Tacrolimus Other prescribers in Milwaukee, WI | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 28 payments worth $28,301 in total to this clinician.
| Incyte Corporation | $16,669 |
|---|---|
| Genzyme Corporation | $10,470 |
| Daiichi Sankyo Inc. | $650 |
| National Marrow Donor Program | $325 |
| Medexus Pharma, Inc. | $169 |
| AbbVie Inc. | $17.45 |
| Consulting Fee | $23,944 |
|---|---|
| Travel and Lodging | $3,277 |
| Food and Beverage | $1,080 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Jun 14, 2025 | Consulting Fee | $9,251 |
| Incyte Corporation Dec 1, 2025 | Consulting Fee | $7,193 |
| Incyte Corporation May 8, 2025 | Consulting Fee Niktimvo · Oncology | $6,850 |
| Incyte Corporation Oct 8, 2025 | Travel and Lodging travel to Minneapolis, MN | $897 |
| Daiichi Sankyo Inc. Apr 10, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $650 |
| Genzyme Corporation Jun 7, 2025 | Travel and Lodging travel to San Francisco, CA · in-kind | $545 |
| Incyte Corporation Apr 24, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Denver, CO | $531 |
| Genzyme Corporation Jun 7, 2025 | Travel and Lodging travel to San Francisco, CA · in-kind | $330 |
| Incyte Corporation Apr 25, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Denver, CO | $291 |
| Incyte Corporation Oct 14, 2025 | Travel and Lodging travel to Minneapolis, MN | $231 |
All 15 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Dec 1, 2025 | Consulting Fee | $7,193 |
| Incyte Corporation Oct 15, 2025 | Travel and Lodging travel to Minneapolis, MN | $150 |
| Incyte Corporation Oct 14, 2025 | Travel and Lodging travel to Minneapolis, MN | $231 |
| Incyte Corporation Oct 14, 2025 | Travel and Lodging travel to Minneapolis, MN | $209 |
| Incyte Corporation Oct 8, 2025 | Travel and Lodging travel to Minneapolis, MN | $897 |
| Genzyme Corporation Jun 14, 2025 | Consulting Fee | $9,251 |
| Genzyme Corporation Jun 14, 2025 | Travel and Lodging travel to San Francisco, CA | $54.00 |
| Genzyme Corporation Jun 7, 2025 | Travel and Lodging travel to San Francisco, CA · in-kind | $545 |
| Genzyme Corporation Jun 7, 2025 | Travel and Lodging travel to San Francisco, CA · in-kind | $330 |
| Incyte Corporation May 8, 2025 | Consulting Fee Niktimvo · Oncology | $6,850 |
| Incyte Corporation Apr 25, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Denver, CO | $291 |
| Incyte Corporation Apr 25, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Denver, CO | $22.40 |
| Incyte Corporation Apr 25, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Denver, CO | $18.00 |
| Incyte Corporation Apr 24, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Denver, CO | $531 |
| Daiichi Sankyo Inc. Apr 10, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $650 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $414,011 in research payments for these studies, mostly to the institutions running them.
- A Phase II Trial of De-escalated PTCy and Ruxolitinib for GVHD Prophylaxis in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT
Incyte Corporation - A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplant…
National Marrow Donor Program - A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia
Janssen Research & Development, LLC - AUTO1-AL1
Autolus Inc - A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AM…
Astellas Pharma Global Development - A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic…
National Marrow Donor Program - Facilitating Activation of Study Trials (FAST)
National Marrow Donor Program
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.